BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 18300308)

  • 1. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 3. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 4. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
    Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
    Mayorga J; Richardson-Hardin C; Dicke KA
    Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
    Bi KH; Jiang GS
    Cell Mol Immunol; 2006 Dec; 3(6):421-7. PubMed ID: 17257495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    Ducas RA; Seftel MD; Ducas J; Seifer C
    J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Jin B; Hou KZ; Liu YP; Yu P
    Chin Med Sci J; 2006 Sep; 21(3):171-4. PubMed ID: 17086739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
    Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V
    Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272
    [No Abstract]   [Full Text] [Related]  

  • 17. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 18. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 20. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.